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L-Dopa is the major symptomatic therapy for Parkinson’s disease, which commonly occurs in elderly
patients. However, the effects of chronic use on mood and cognition in old subjects remain elusive. In
order to compare the effects of a chronic pulsatile L-Dopa treatment on emotional and cognitive func-
tions in young (3 months) and old (18 months) intact rats, an L-Dopa/carbidopa treatment was admin-
istered every 12 h over 4 weeks. Rats were assessed for behavioural despair (repeated forced swimming
test, RFST), anhedonia (sucrose preference test, SPT) and spatial learning (Morris water maze, MWM) in
the late phase of treatment (T). Neuronal expression of Fos in the hippocampus at the early and late
phases of T, as well as after MWM was studied. The density and ratio of dopamine D5r, D3r and D2r
receptors were also evaluated in the hippocampus using immunohistochemistry and confocal micro-
scopy. Young rats showed similar patterns during behavioural tests, whereas aged treated rats showed
increased immobility counts in RFST, diminished sucrose liquid intake in SPT, and spatial learning
impairment during MWM. Fos expression was signiﬁcantly blunted in the aged treated group after
MWM. The density of D5r, D3r and D2r was increased in both aged groups. The treatment reduced the
ratio of D5r/D3r and D5r/D2r in both groups. Moreover, aged treated subjects had signiﬁcant lower
values of D5r/D3r and higher values of D5r/D2r when compared with young treated subjects. These
results indicate that chronic L-Dopa treatment in itself could trigger emotional and cognitive dysfunc-
tions in elderly subjects through dopamine receptor dysregulation.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
L-3,4-dihydroxyphenylalanine (L-Dopa or levodopa) is the direct
precursor of dopamine (DA) (Elsworth and Roth, 1997; Nutt, 1987)
and has been suggested to have direct effects on DA receptors
(Goshima, 1993). It is widely used in the therapy of Parkinson’s
disease (PD) (National Collaborating Centre for Chronic Conditions
(UK), 2006) and has also been used, although to a minor extent, to
treat some neurological and psychiatric disorders such as Alz-
heimer’s disease (Martorana et al., 2008) and schizophrenia (Jaskiw.
r Ltd.Open access under CC BY-NC-NDand Popli, 2004). It has been implicated as a potential substance for
drug abuse (Limotai et al., 2012; Spigset and von Scheele, 1997;
Witjas et al., 2012).
Whether the use of L-Dopa can induce DA system dysregulation
in treated subjects is controversial (Macdonald and Monchi, 2011).
Although there are several studies showing that L-Dopa is toxic
in vitro (Corona-Morales et al., 2003, 2000; Mytilineou et al., 2003),
there is little convincing evidence suggesting that L-Dopa, at its
therapeutic dose, exerts dysregulatory effects on the in vivo dopa-
minergic system (Evans and Lees, 2004; Olanow et al., 2009). The
plasmatic half-life of thewidely used L-Dopa/carbidopa is about 21/
2 h (Chana et al., 2003). Hence, a twice-daily L-Dopa/carbidopa
therapeutic scheme produces pulsatile intracerebral L-Dopa con-
centration (Schapira, 2003). Furthermore, the erratic absorption of license.
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neurotransmitter-receptor systems compensate for over- or under-
stimulationwith a reduction in responsivenessordesensitization, or
an enhanced responsiveness or supersensitivity, respectively. In
general, results from in vivo and in vitro studies of DA receptor
regulation ﬁt within this scheme (Creese et al., 1981; Sibley and
Neve, 1997). However, the functional limits of this resilience
mechanism can be surpassed by external or internal factors, such as
drug dose, pulsatility, ageing, etc. It is commonly accepted that DA
D1r-class of receptors (D1r and D5r) activates the Gas/olf family of G
proteins to stimulate cAMP production by adenylyl cyclase (AC).
These are found exclusively postsynaptically on dopamine-
receptive cells. D5r is highly expressed in the hippocampus (Ciliax
et al., 2000; Jay, 2003; Marsdan, 2006; Meador-Woodruff et al.,
1992; Sunahara et al., 1991). The DAD2r-class of receptors (D2r, D3r,
and D4r) couples to the Gai/o family of G proteins and thus induces
inhibition of AC. In contrast to the D1-class of DA receptors, D2r and
D3r DA receptors are expressed both postsynaptically and presyn-
aptically (Beaulieu and Gainetdinov, 2011; Sokoloff et al., 2006) and
are highly expressed in the hippocampal region (Khan et al., 1998).
D2r and D3r have been reported to bemodiﬁed prominently during
the L-Dopa treatment (Joyce, 2001; Joyce et al., 2004).
DA critically contributes to cellular consolidation of
hippocampal-dependent memories by modifying synaptic plas-
ticity in hippocampal neurons (Frey et al., 1991; O’Carroll et al.,
2006), and is particularly sensitive to ageing (Amenta et al.,
2001). Hippocampal dopaminergic innervation arises mainly from
the midbrain, and is part of the mesolimbic dopaminergic pathway
(Scatton et al., 1980; Swanson, 1982). It has been shown that acti-
vation of the ventral tegmental area (VTA) leads to DA release in the
hippocampus (Jay, 2003). Recent studies (Bolam and Pissadaki,
2012; Pissadaki and Bolam, 2013) have suggested that the unique
cellular architecture of both the nigro-striatal and mesolimbic
dopaminergic pathways makes them differentially susceptible in
PD. Substantia nigra pars compacta (SNc) DA neurons possess large,
complex axonal arborizations, which put them under a tight energy
budget that makes them particularly susceptible to factors that
contribute to cell death. However, this seems not to be the case for
mesolimbic VTA DA neurons (Bolam and Pissadaki, 2012). Hence,
the effects of a systemically increased L-Dopa availability can have
differential impacts on the nigro-striatal and mesolimbic dopami-
nergic pathways, and the latter modulates emotionality and
cognitive function (Nieoullon and Coquerel, 2003).
In view of the above ﬁndings, it becomes important to ask
what the impact(s) of the systemic increase of L-Dopa availability
are on the mesolimbic dopaminergic pathway. One strategy to
dissect them is to expose young and old rats to chronic and
pulsatile L-Dopa treatment and subsequently examine them for
possible mood and cognition impairments with well-validated
tests. Hence, we hypothesize that a global increase in the dopa-
minergic tone, due to L-Dopa administration, can impair cogni-
tive and emotional functions in old subjects possibly through
modiﬁcation of dopaminergic receptors. We have evaluated this
hypothesis using a hippocampus-dependent spatial learning task
and the consequences of L-Dopa treatment on the activation of
the hippocampus by assessing the expression of the immediate
early gene Fos as well as the dopaminergic receptor densities and
their ratios.
2. Material and methods
2.1. Animals and treatment
Sixty-eight male Wistar rats from the local animal facility were used in this
study. All animal procedures were approved by the local bioethical and research
committees in accordance with the principles exposed in the National Institute of
Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23) revised 1996. Rats were housed two per cage, maintained on an inverted 12-h
light schedule in a room with controlled temperature between 20 C and 24 C
with adequate ventilation, and given access to standard rat chow and water ad
libitum.
Rats were separated into two groups. The “Young” group comprised of 34 three-
month old male rats (250 g  15 g b. w.): 17 “Control Young” and 17 L-Dopa-treated
“L-Dopa Young”. The “old” group comprised of 34 eighteen-month old male rats
(600 g  25 g, b. w.): 17 “Control Old” and 17 L-Dopa-treated “ L-Dopa Old”. The
experimental young and old groups were treated with oral L-Dopa/carbidopa dose
25mg/2.5 mg per kg, (Sinemet 250/25 mg, L-Dopa/carbidopa, Merck & Co., Inc.)
twice daily (period T¼ 12 h). The tablet was grinded and the corresponding amounts
were mixed with soft cheese pellets (approximately 1 g of wet weight per pellet).
Experimental subjects were previously habituated with the soft-cheese pellets for
about 3 days until the rats ate the pellets readily. The experimenterwatched over the
drug/cheese intake process until each subject ate the corresponding pellet in its
entirety. This administrationwas continued for four weeks in a twice-daily schedule
(at the beginning of the light- and dark- periods). The control groups received the
soft-cheese pellets only, in the same schedule.
The reason for which we used this unconventional drug administration method
is because we aimed to examine mood and cognition functions in young and old rats
under a chronic and pulsatile treatment of L-dopa e our experimental-treatment
variable. It was important to avoid any treatment-related stressful events, such as
oral gavage or intraperitoneal injection. Based on this reasoning, we established this
low-stress drug/soft-cheese co-administration method. Both cheese (in pellets of
1 g) and drug (corresponding dosage per subject) were weighed using an analytical
balance before being mixed. After a 3-day training period in which we gave only
cheese pellets directly to the rats, the pellets were completely eaten as soon as they
were introduced to the cage, on small weighing boats (generally in less than 30 s). In
this way, wewere able to administer the precise dosage of drug without introducing
signiﬁcant stress, an important condition for the behavioural tests.
2.2. Behavioural assessments
All behavioural assessments were carried out at the late phase of the T, i.e. after
more than 10 h of the last L-Dopa dose.
2.2.1. Repeated forced swimming test (RFST)
After 4 weeks of L-Dopa treatment, young and old rats (n ¼ 7) were assessed for
depressionelike behaviour using a modiﬁed version of forced swimming test in
which experimental subjects were repeatedly exposed to the swimming stressor.
Brieﬂy, the modiﬁed Porsolt forced swim test paradigm used (Porsolt et al., 1977a;
Zhang et al., 2008) (McLaughlin et al., 2003) was a 2-day procedure in which rats
swamwithout the opportunity to escape. In all trials, rats were placed in a Plexiglas
cylinder (45 cm tall  30 cm in diameter) containing 30 cm of water, kept at 24 C.
After the trial, rats were removed, dried with towels, and returned to their home
cages for at least 10 min before further testing. On day 1, animals were placed in
water to swim for a single trial of 15 min. The time spent immobile in the last 5 min
of the trial was recorded. On day 2, animals were again placed in water to swim but
in a series of four trials, each 6min long. Trials were separated by a 12e15min return
to a home cage. Swimming behaviour was recorded with a video camera, and
immobility duringminutes 2e6 was analysed off-line according to criteria described
elsewhere (Detke et al., 1995; Zhang et al., 2008). Brieﬂy, the observer gave a score of
either “swimming” or “immobile” every 5 s. A ratwas judged to be immobilewhen it
remained ﬂoating, making only minimum necessary movements to keep its head
over the surface without horizontal displacement. Percentages of immobility counts
out of total counts (60) were calculated.
2.2.2. Sucrose preference test (SPT)
After the forced swimming test, the same rats were singly housed and presented
to a sucrose solution drop dispenser (3% sucrose in H2O) and a plain water drop
dispenser side by side during 24 h in order to let the rats habituate to the sweet
liquid. Concluding this period, the dispensers were removed and the rats underwent
water deprivation for 6 h. Subsequently, the drop dispensers with a previously
quantiﬁed liquid volume were placed in the same locations for the next 24 h
allowing the rats to drink ad libitum and undisturbed. Completing this period, the
liquid consumption was measured and the sucrose liquid drinking volume, as a
percentage of the total liquid consumption, was calculated. This test has been used
for anhedonia assessment and was ﬁrst described by Willner et al. (Willner et al.,
1987).
2.2.3. Morris water maze (MWM)
After 4 weeks of L-Dopa treatment, spatial learning was evaluated with a
separate set of rats (n ¼ 10) during the beginning of the dark period, using a
modiﬁed version of MWM described elsewhere (Hernandez et al., 2012; Nissen
et al., 2012). Rats were exposed to the swimming pool without the platform for
2 min one day before, aiming to habituate them to this experimental procedure and
reduce the stress caused by novelty. The test consisted of eight consecutive trials
with 5 min rest intervals and was video-recorded. Off-line blind analysis was made.
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alterations, the swimming speed in the ﬁrst trial was measured as follows: the
swimming paths weremanually traced using an acetate projection sheet placed on a
monitor and traced with a marker while playing the experimental recording.
Swimming velocity was measured only when rats were swimming and ﬂoating
movements were eliminated. The tracings were then digitalized and the swimming
distance per minute was measured with the “NeuroJ” plugin for ImageJ (Meijering
et al., 2004). Path lengths were divided by latencies and velocity was obtained
(expressed as cm/s).
2.3. Immunohistochemistry (IHC)
For perfusion-ﬁxation, rats were deeply anesthetized with an overdose of
pentobarbital (63 mg/kg) and perfused for 15 min transcardially with 0.9% saline
followed by cold ice ﬁxative containing paraformaldehyde 4% in 0.1M sodium
phosphate buffer (PB, pH 7.4) plus 15% v/v of saturated picric acid. After perfusion,
the brains were removed from the skull, thoroughly rinsed with PB and brain
vibratome sections of 70 mmwere collected.
2.3.1. IHC against Fos
To evaluate the neuronal activity the protein product of the proto-oncogene fos
was used (Kovacs, 1998). Fos is best detected in the interval between 60 and 120min
after a neuron is activated (Kovacs,1998). Hence, we chose the following time-points
after the last L-Dopa administration: a) early phase of T: 3 h after last L-Dopa
administration (Basal 3 h, n ¼ 4); b) late phase of T: 12 h after last L-Dopa admin-
istration (Basal 12 h, n ¼ 4); c) sixty minutes after MWM test (MWM, n ¼ 4). It is
worth mentioning that L-Dopa plasmatic concentration peaks around 2 h after
administration and drops to a negligible level at 10e11 h after administration (Chana
et al., 2003; Khor and Hsu, 2007). Hence, the late phase of T represented a virtual
abstinence phase.
For IHC, every third section spanning from Bregma e 3.6 mm to Bregma e
4.3 mm, according to the Paxinos and Watson brain atlas (Paxinos G, 1998), were
blocked with 20% normal goat serum (NGS) in Tris-buffered (0.05M, pH 7.4) saline
(0.9%) plus 0.3% of Triton X-100 (TBST) for 1 h at room temperature (RT) and then
immunoreacted overnight with rabbit anti-Fos primary antibody (SC52, 1:1000,
Santa Cruz Biotechnology, Santa Cruz, CA) in TBST þ1% NGS at 4 C with gentle
shaking. Afterwards, sections were rinsed three times for 10 minwith TBST and then
incubated for 2 h at RTwith biotinylated goat anti-rabbit secondary antibody (1:200;
Vector Labs, Burlingame, CA). Finally, sections were incubated in avidin-biotin-
peroxidase complex (Elite ABC kit, Vector Labs) for 1 h at RT. Peroxidase was
detected using diaminobenzidine 0.05% as chromogen. Sections were rinsed and
permanently mounted with Permount mounting medium (Electron Microscopy
Sciences, Hatﬁeld, PA). Fos immunoreactive nuclei per 540 mm of length of cell body
layers were counted using a Nikon Eclipse 50i microscope and a drawing tube.
2.3.2. IHC against dopamine receptors
Four rats per group were perfused as previously described (Section 2.3). One
sagittal section per subject, containing dorsal and ventral hippocampus (lateral
3.9 mm according to the Paxinos and Watson brain atlas (Paxinos G, 1998), was
selected for IHC against the DA receptors. It is worth noting that the ﬁxation, cutting
and IHC procedures were strictly controlled to be uniform for all rats and all the
freely ﬂoating brain sections were labelled with different cuts and underwent the
IHC reaction inside the same vial. Sections were blocked with 20% normal donkey
serum (NDS) in Tris-buffered (0.05M, pH 7.4) saline (0.9%) plus 0.3% of Triton X-100
(TBST) for 1 h at RT and then immunoreacted overnight with the following primary
antibodies: guinea pig against D2r (1:1000, Frontier Institute, Af500); rabbit against
D3r (1:1000, Chemicon, AB1786p); mouse against D5r (1:1000, Chemicon,
MAB5292). After the incubation, the slices were washed three times with TBST and
incubated for 2 h with the following secondary antibodies: CY5 donkey against
guinea pig (AP193S, Millipore); Alexa 594 donkey against rabbit (A-21207, Molecular
probes); Alexa 488 donkey against mouse (A-21202, Molecular probes). Sections
were rinsed and mounted with Vectashield mounting medium. Analysis of signal
intensity was done in photographs taken at 20with a confocal Leica microscope at
1.5 mm of thickness. For image acquisition and initial observation, Leica LASAF
softwarewas used, while the Fiji version of ImageJ (Schindelin et al., 2012), was used
to calculate the signal intensity, in 50 mm 50 mmareas inside the cell body layer for
each reading of the corresponding receptor at CA1, CA2, CA3 and dentate gyrus
regions.
2.4. Data analyses
Quantitative results were expressed as mean  SEM. Multiple pair-comparisons
were performed using Bonferroni post hoc test after ordinary one-way, two-way or
three way analysis of variance (ANOVA), speciﬁed in the “result section” for each
experiment. For RFST, second day analysis, andMWM, repeatedmeasures analysis of
variance (RM-ANOVA) followed by Bonferroni post hoc test were used, where ‘trials’
was the within-subject factor and ‘treatment’ was the between-subject factor. Post
hoc differences were considered statistically signiﬁcant at a value p< 0.05 (*p< 0.05,
**p < 0.01, ***p < 0.001).In order to better understand each population’s dynamic behaviour during the
MWM spatial learning task, probability of escape was analysed. The escape latency
of the individuals was treated as a different data point and then its frequency was
collected using bins of ﬁve seconds for each of the four groups (Age e Treatment).
The frequency count was used to construct the cumulative frequency distribution.
The normalization of the cumulative frequency to the total of data points in each
population deﬁnes the cumulative probability function of escape latency (CPFEL).
Then a cumulative Weibull distribution function was ﬁtted to the CPFEL using
Matlab R2012a (MathWorks Inc., Natick, MA). The cumulative Weibull distribution
functionf ðxÞ ¼ 1 eðt=lÞk , where k is the shape parameter and l is the scale
parameter, was chosen and is commonly used in survival analysis. The cumulative
distribution function obtained in this way provided additional information about
the groups analysed because it better ﬁts the naturally random aspects of rat
behaviour, and because it is a direct measure of the probability of escape. It also
allows us to determine the halftime of escape and the spread of the escape latency
distribution. In order to test for statistical differences between the models, we
compare the resulting parameters from the non-linear ﬁt with an F statistic. As it
will be shown below, this analytical model has the advantage that it naturally fol-
lows the logic of the experiment and it is able to reveal new characteristics in the
interpretation of the MWM spatial learning behaviour.
3. Results
3.1. Behavioural despair measured with RFST was only observed in
the old-treated group
The repeated forced swimming test (RFST) allows for the
assessment of depression-like behaviour, on both acute (ﬁrst day of
the test) and repeated exposure (second day of the test) and helps
to rule out the possibility of motor impairments. Seven rats per
experimental group were exposed to the RFST. For the ﬁrst day
data, one-way ANOVA was applied. The analysis showed that the
percentage of immobility differed signiﬁcantly between age
groups, (p < 0.01, F (3,27) ¼ 6.816), but not between treatments
within the same age group.
For the second day data, repeated measure-two-way ANOVA
was used. Analysis showed that in both age groups, the effect of the
factor trialwas signiﬁcant (p< 0.001, F (3,36)¼ 35.31 for young and F
(3,36)¼ 40.66 for old subjects). Treatment had no signiﬁcant effect on
young rats (p ¼ 0.427, F (1,36) ¼ 0.675), however a signiﬁcant effect
was shown on old rats (p < 0.01, F (1,36) ¼ 11.09). No interaction
between treatment and trial was found in either group. Young
control and L-Dopa-treated rats showed similar immobility pat-
terns along the entire course of the test (Fig. 1A). In contrast, old
animals treated with L-Dopa showed a signiﬁcant increase in
immobility in trials II (p < 0.01), III (p < 0.05) and IV (p < 0.05) of
the second day of the test when compared to the corresponding
control group (Fig. 1B).
3.2. Sucrose intake test revealed anhedonia in L-Dopa treated old
rats
Anhedonia, a behavioural expression of hyposensitivity to
reward, is interpreted as a symptom of depression and is commonly
tested in rats as a decreased consumption of a sweet palatable
solution. After 4 weeks of pulsatile L-Dopa administration, anhe-
donia was assessed by means of the sucrose (3% sucrose solution)
intake test in a 24hr period. One-way ANOVA showed that the
percentage of sucrose intake in old rats treated with L-Dopa was
signiﬁcantly reduced compared with all other groups (p < 0.001, F
(3,27) ¼ 42.94) (Fig. 2).
3.3. Chronic pulsatile L-Dopa treatment effectively impaired spatial
learning in old rats
The effect of the long-term pulsatile administration of L-Dopa on
spatial learning was tested using the MWM test. Data was analysed
using a mixed model analysis of variance (ANOVA) of the MWM
Fig. 1. Behavioural despair assessed by repeated forced swimming test (RFST). Histograms show the percentage of immobility episodes that occurred in the young (A) and old (B)
groups. Day 1: the last 5 min of a 15 min trial were assessed; day 2: the last 5 min in each of four 6 min trials were assessed. Values represent mean  SEM, *P < 0.05, **P < 0.01,
n ¼ 7. C.Y.: control young; L.Y.: L-dopa young; C.O.: control old; L.O.: L-Dopa old.
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(cheese pellets with or without L-Dopa) and trial with repeated
measures (I, II, III, IV, V, VI, VII, VIII). The non-sphericity of the data
was signiﬁcant, as reported from the Mauchly test. To correct for
the nonesphericity, we used the Huynh - Feldt correction. Using
this correction, three factor interaction was signiﬁcant, F
(4,193) ¼ 2.815, p ¼ 0.023. Then, in order to search for the in-
teractions we restricted our analysis to a mixed model ANOVA
leaving the age factor ﬁxed, again assigning the factor trial as the
repeated measures.
In the young rat group, the interaction between trial and treat-
mentwas not signiﬁcant, F (7, 154)¼ 0.821, p¼ 0.571. The main effect
trial was signiﬁcant, (F (7,154) ¼ 47.245, p < 0.001). These results
indicate that the spatial learning process increases with repetition
(Fig. 3A), but there was no effect of the treatment in the young
group. In the case of the old group, both the interaction and the
main effect were signiﬁcant: F (7,154) ¼ 5.101, p < 0.001 and F
(7,154) ¼ 34.6, p < 0.001. Then again, the learning process was
different along between the trials but a signiﬁcant difference due to
the treatment is shown(Fig. 3B). The Bonferroni post hoc test
showed that both the young and old control rats found the platform
in signiﬁcant less time compared to the L-Dopa treated aged rats in
trials III, V and VII. Fig. 3C combined the panels A and B. In this
panel, a subtle difference between the control groups (young vs.
old) can be seen (see insert of panel D, where we analyse the curve
“shape” parameter kappa (one can easily observe the similitude
inside and the difference between the age groups). Fig. 3D shows
the cumulative probability of the escape latency (CPFEL) for the
different groups. The symbols represent the experimental data and
the segmented lines the corresponding non e linear ﬁt. A clear
difference in the CPFEL was observed for the L-Dopa old group inFig. 2. Anhedonic behaviour measured by the sucrose preference test (SPT). Histo-
grams show the percentage of sucrose intake related to the total volume of liquid
consumption (plain water þ water with 3% of sucrose). Values represent mean  SEM.
***P < 0.001, n ¼ 7. C.Y.: control young; L.Y.: L-Dopa young; C.O.: control old; L.O.: L-
Dopa old.which half of the population reached the platformwith times lower
than 22.5 s. The insert in Fig. 3D shows the estimators for the shape
(k) and the scale (l) parameters (open symbols) with their 95% CI
(error bar). The estimators are showed in segmented lines in the
inset. It can also be seen that the halftime of escape is greater only
for the old treated group (Fig. 3D, right insert), while the halftime of
escape for the three other groups is statistically the same. None-
theless, the data distribution for the control old group, reﬂected by
the curve shape estimator (k), was different compared to the young
groups (Fig. 3D, left insert). With this representation, the individual
variation became part of the population behaviour and the differ-
ences between the groups could be clearly visualized.3.4. The L-Dopa treatment did not produce locomotor alterations as
revealed by swimming speed analysis
The swimming speed measured for the ﬁrst trial of the MWM
test is showed in Table 1. No differences were found between
control and L-Dopa treated groups, whereas signiﬁcant differences
were detected between age groups (Table 1).3.5. “Spontaneous” Fos expression in hippocampus at “basal 12 h”
in the treated groups and dampened Fos induction by MWM in the
old treated group
The expression of Fos was evaluated in the hippocampus (CA1,
CA3 and DG) after 4 weeks of pulsatile L-Dopa administration at
three different time-points: 3 h and 12 h after the last L-Dopa
administration, and 1 h after MWM using immunohistochemical
method (see Fig. 4, panels A, B, C and inserts as examples of these
immunoreactions). Using a three-way ANOVA analysis (factors: age,
treatment, time), we observed that for CA3, the time, age, treatment
and all second order and third order interactions had a signiﬁcant
effect (time: F (2,372) ¼ 814.99, p < 0.001; treatment: F (1,372) ¼ 4.91,
p < 0.02; age: F (1,372) ¼ 26.51, p < 0.001; time.treatment: F
(2,372) ¼ 17.49, p < 0.001; treatment.age: F (1,372) ¼ 4.91, p ¼ 0.027;
time.age: F (2,372) ¼ 14.18, p < 0.001; treatment.age.time: F
(2,372) ¼ 4.72, p ¼ 0.009). For CA1 the main effect of time and
treatment as well as its interaction, the interaction of time and age
and the three order interaction had a signiﬁcant effect (time: F
(2,372) ¼ 961.7, p < 0.001; treatment: F (1,372) ¼ 14.15, p < 0.001;
time.group: F (2,372) ¼ 4.0, p ¼ 0.019; treatment.age: F (1,372) ¼ 5.74,
p¼ 0.071; treatment.age.time: F (2,372)¼ 5.82, p¼ 0.003). For DG the
third order interaction and the second order interaction treat-
ment.age were not signiﬁcant, therefore we ﬁtted a simple model
without these terms (time: F (2,375)¼ 445.43, p< 0.001; treatment:
F (1,375) ¼ 25.51, p < 0.001; age: F (1,375) ¼ 20.58, p < 0.001,
Fig. 3. Mean latency of escape from the Morris Water Maze test comparing control and L-Dopa treated groups in young (A) and old subjects (B) and comparison of the performance
of the 4 groups (C) (n ¼ 10; *p < 0.05; **p < 0.01). (D) Cumulative probability of escape latency (CPFEL) from the Morris Water Maze test. Note that the cumulative probability of
escape was lower for the L-Dopa treated old group (L.O) than for any other group at any time. The probability of scape of 50% of the population, other than the L.O., presented a
latency time lower than 10 s (less than half of the time for the L.O.). The insert shows the comparison of the parameters k and l from the non-linear ﬁt of the Weibull distribution
function. It can be noticed that the values for k groups/cluster seem to draw together in young and old groups, but the difference is signiﬁcant between them. On the other side, the l
parameter is different only for the L.O. (For details see discussion in the text). C.Y.: control young; L.Y.: L-Dopa young; C.O.: control old; L.O.: L-Dopa old.
V.S. Hernández et al. / Neuropharmacology 82 (2014) 88e10092time.treatment: F (2,375) ¼ 17.19, p< 0.001; time.age: F (2,375)¼ 24.83,
p < 0.001). Post hoc Bonferroni test was used to compare the data
from different time but within the same group and same hippo-
campal subﬁeld. The results are reported in the table at the end of
Fig. 4.
Minimum Fos expression levels were found in all groups at 3 h
after the last administration of L-Dopa, (Fig. 4, panel A and blue bars
of panels D, E, F). However, at the 12 h point, young and old treated
animals showed a signiﬁcant increase (p < 0.001) in the neuronal
activation in the CA3 and DG hippocampal subﬁelds (Fig. 4, panel B
and green bars of panels D, E, F). The spatial learning test induced a
further signiﬁcant increase of Fos expression in all groups when
compared with the basal 12 h condition (p < 0.001) (Fig. 4, panel C
and red bars of histograms D, E and F). However, the relative Fos
elevation induced by the MWM was blunted in the old treated
group, especially in the DG (Fig. 4, panel F, C.O vs L.O., shade
segments).
3.6. The density of D5r, D3r and D2r was increased in the old groups
and the treatment differentially modiﬁed the ratios D5r/D3r and
D5r/D2r, between the age groups
Using IHC and confocal microscopy, D5r, D2r and D3r optical
density measurements were performed in the CA1, CA2, CA3 andTable 1
First trial speed analysis.
Young (cm/s) Old (cm/s)
Control 20.8  2.9 14.2  1.8 p < 0.01
L-Dopa 22.1  1.8 14.6  2.1 p < 0.01
ns ns
ns: not signiﬁcant.DG hippocampal subﬁelds, the results of a two-way ANOVA anal-
ysis (treatment þ age pooled as group), showed signiﬁcant effects
of: group (p < 0.001; CA1: F (3,138) ¼ 777.9; CA2: F (3,108) ¼ 469.5;
CA3: F (3,180) ¼ 359.9; DG: F(3,138) ¼ 334), receptor subtype
(p < 0.001; CA1: F (2,138) ¼ 135.8; CA2: F (2,108) ¼ 248.5; CA3: F
(2,180)¼ 234.4; DG: F(2,138)¼ 251.5), and interaction (p< 0.001; CA1:
F(6,138) ¼ 45.26; CA2: F(6,108) ¼ 44.39; CA3: F(6,180) ¼ 23.09; DG:
F(6,138) ¼ 16.61). The results for the receptor density ratios showed
also signiﬁcant effects of group (p < 0.001; CA1: F (3,92) ¼ 305.3;
CA2: F(3,72) ¼ 226; CA3: F(3,120) ¼ 102.8, DG: F(3,92) ¼ 8.67), receptor
density ratio (p < 0.001; CA1: F(1,92) ¼ 323.5; CA2: F(1,72) ¼ 611.3;
CA3: F(1,120) ¼ 585.4, DG: F(1,92) ¼ 65.3) and interaction (p < 0.001,
CA1: F(3,92) ¼ 22.42; p < 0.001, CA2: F(3,72) ¼ 70.16; p < 0.001, CA3:
F(3,120) ¼ 44.9, p < 0.05, DG: F(3,92) ¼ 3.85). A Bonferroni post-hoc
test to compare receptor densities or receptor density ratios be-
tween groups within each region was performed.
By performing confocal microscopic observation, we found that
D5r, D3r and D2r were mainly localized at the somata and the
proximal segments of the main dendrites (Fig. 5, panels A0 and B0
and Fig. 6). The distribution of immunoreactivity for the three
studied receptors was not homogeneous through the hippocampus
subﬁelds but displayed a CA2/3, CA1 and DG gradient. A signiﬁ-
cantly increased density of the D5r, D3r and D2r was found in the
aged control group as compared with the young control rats (Fig 5,
A panels compared to B panels, and histogram of 5C). L-Dopa
treatment had no effect on D5r expression in young subjects, except
in DG where a reduction was observed. In contrast, the treatment
enhanced the D5r expression in aged rats in all hippocampal re-
gions evaluated. Conversely, the treatment enhanced globally the
D3r and D2r expression in both young and aged rats, except in CA3
and DG of young subjects where no signiﬁcant differences were
detected (Fig. 6, panels As and Bs, C, D, E, F),
Fig. 4. Hippocampal Fos expression observed at time-points “Basal 3 h”, “Basal 12 h” and 1 h post MWM conditions. Panels A, B, and C, photomicrographs of typical Fos expression
patterns in aged hippocampus under the three conditions above mentioned. Scale bars: 1 mm for A, B and C; 200 mm for inserts. Histograms show the number of Fos positive nuclei
in CA1 (D), CA3 (E) and dentate gyrus (F) under the three experimental conditions: “Basal 3 h”: blue bars, “Basal 12 h”: green bars and “MWM”: red bars. Bars with unequal lettering
are statistically different at p < 0.05. Table underneath histograms reports statistic results between experimental conditions within the same age/treatment group. C.Y.: control
young; L.Y.: L-dopa young; C.O.: control old; L.O.: L-Dopa old. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
V.S. Hernández et al. / Neuropharmacology 82 (2014) 88e100 93
Fig. 5. Hippocampal dopamine receptor expression in control rats. A and A0 and As: low and high magniﬁcation of immunoﬂuorescence photomicrographs of ventral hippocampus
of old rat. D5r (red), D3r (green) and D2r (blue); B and B0 and Bs: the same region of a young rat processed with the same immunohistochemical conditions. Scale bars: A, B: 500 mm;
As and Bs: 50 mm; A0 and B0: 10 mm. G. C and D: Histograms showing the immunoﬂuorescence optical density differences of D5r, D3r, D2r in dorsal (dHi) and ventral (vHi) hip-
pocampal cell body layers between old and young control subjects (C) and the ratio between D5r/D3r, D5r/D2r in the above regions. ***p < 0.001, **p < 0.01. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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ratios as consequences of ageing and L-Dopa treatment. Because
binding of D5r and D2r/D3r produces opposing inﬂuences on
adenylyl cyclase signalling cascades, as previouslymentioned in the
“Introduction”, and the experimental data mentioned aboveindicated that the three DA receptors studied here were mostly co-
expressed in the same cellular compartments, the ratio of D5r/D3r
and D5r/D2r become important factors for dopaminergic neuro-
transmission homeostasis (Neve, 2005; Thompson et al., 2010). The
assessment of these indicators after chronic L-Dopa treatment
Fig. 6. Hippocampal cell body layer co-expression of D5r, D3r and D2r of young and old, control and L-Dopa treated rats. As and A’s showing the expression patterns of young
control and young treated subjects, respectively, and Bs and B’s are from the old counterparts/cohorts. Scale bars: 500 mm. Panels C, D, E, F: histograms showing the immuno-
ﬂuorescence optical density of D5r, D3r and D2r in the dorsal hippocampus CA1, CA2, CA3 and DG respectively, of the four experimental groups. C0 , D0 , E0 and F0 show the D5r/D3r
and D5r/D2r ratios analysis of the respective subﬁelds and experimental groups. Bars with unequal lettering are statistically different at p < 0.05.
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regulation in different treatment/age groups.
Ageing per se produced reduction in the ratio of D5r/D3r in CA1
and CA2 regions, and D5r/D2r in CA 1e3 in control rats (old rats vs.
young rats) (Fig 5D). Treatment further globally reduced these ra-
tios (Fig. 6, C0eF0). Moreover, aged treated subjects had signiﬁcantly
lower values of D5r/D3r and higher values of D5r/D2r when
compared with young treated subjects in most of the regions
evaluated (Fig. 6, C0, D0, E0, F0).4. Discussion
The results from this series of experiments provide the ﬁrst
evidence that chronic treatment with a therapeutic dose of L-Dopa
could exert an age-dependent effect regarding the genesis of
depression-like behaviour, anhedonia and cognitive dysfunction. A
blunted Fos induction after performing a spatial learning task in the
old treated group, compared both with its age-control group and
treatment-reference fromyoung rats, indicates that the age-related
Fig. 6. (continued).
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ceptible to a centrally acting drug, such as L-Dopa.We also observed
a signiﬁcant reduction in the ratios between D5r/D3r and D5r/D2r
in both treated groups compared with their respective controls,
which is consistent with previously reported data (Beaulieu and
Gainetdinov, 2011; Creese et al., 1981; Sibley and Houslay, 1994).
Surprisingly, however, we found differential reductions in D5r/D3r
and D5r/D2r by the treatment between the age groups: signiﬁcant
lower values for D5r/D3r and higher values for D5r/D2r were
observed when comparing old vs. young treated subjects. A func-
tional interpretation of this ﬁnding is currently lacking.Nevertheless, our data suggests that ageing plays a crucial role on
DA receptor dysregulation in L-Dopa treated subjects.
4.1. The effects of a long-term pulsatile L-Dopa treatment on
hippocampus dependent spatial learning in aged subjects
Previous reports have found that after long-term administration
of L-Dopa, normal monkeys developed L-Dopa-induced dyskinesia
(Pearce et al., 2001; Togasaki et al., 2001). However, young rats
treated with one daily dose of L-Dopa for ﬁve days showed an
improvement in learning and memory tests (Reinholz et al., 2009).
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after the last L-Dopa administration, but studies on other time-
points during the pulsatile drug administration cycle were
missing. Moreover, there is an absence of well-controlled studies
on the effect of L-Dopa on cognition and emotionality in old sub-
jects in spite of it being a therapeutic agent commonly used in
elderly people with PD. DA modulatory effect for cognitive func-
tions is a complex phenomenon and subtly controlled by the
temporal variation of the levels of ligand/receptors and the pres-
ence of growth factors (for instance, brain derived neurotrophic
factor regulate D3r expression in a development-dependent
manner (Guillin et al., 2001).
There are few studies assessing the effects of chronic L-Dopa
treatment in an intact dopaminergic system ((Hagenah et al., 1999)
for instance). Some studies in humans have shown cognition
improvement in subjects given L-Dopa after stroke, brain trauma or
hypoxic-ischemic episodes (Knecht et al., 2004). However, young
subjects were always used in those reports (Mytilineou et al., 2003)
(Reinholz et al., 2009). It has been reported that most of the bio-
physical properties of hippocampal neurons in aged subjects remain
constant over the life span (Burke and Barnes, 2006). These include
resting membrane potential, membrane time constant, input resis-
tance, threshold to reach an action potential, and the width and
amplitude of Naþ dependent action potential (for a review, see
(Burke and Barnes, 2006)). However, subtle changes in Ca2þ
conductance in aged neurons have been reported. CA1 pyramidal
neurons in the aged hippocampus have an increased density of L-
type Ca2þ channels (Thibault and Landﬁeld,1996) thatmight lead to
disruptions inCa2þhomeostasis (Toescuet al., 2004), contributing to
the plasticity deﬁcits that occur with ageing. DA innervation in
hippocampus, arisen mainly from the midbrain dopaminergic
pathways, plays an important modulatory role for hippocampal
function (Wittmann et al., 2005). Long-term potentiation in the
hippocampus can be enhanced and prolonged by dopaminergic
inputs frommidbrain structures (Morris et al., 2003).
Ontheotherhand, ithasbeen reported since the late80’s thatafter
L-Dopa loading, DA, DOPAC and HVA are increased in striatum, hy-
pothalamus, hippocampus and cerebellum,with the largest increases
in those tissues with less dopaminergic activity (el Gemayel et al.,
1986). This study suggested alternative sources of DA release in
those regions. Recent studies have demonstrated that serotonergic
innervations to hippocampus serve as an important source of DA
release induced by L-DOPA treatment (Navailles et al., 2010, 2013).
DA D1 and D5 receptors are involved in the persistence of LTP
(Frey et al., 1991; Swanson-Park et al., 1999). On the other hand,
Otmakhova and Lisman showed that DA strongly inhibits the
response to perforant pathway (pp) stimulation (IC50; 3 mM), but
not the response to Schaffer collateral stimulation (Otmakhova and
Lisman, 1999). DA reduces both the NMDA and AMPA components
of transmission at the pp (Otmakhova and Lisman, 1999). The data
from this study showed that there is a natural increase of the D5r,
D3r and D2r densities in the normal ageing rat hippocampus. This
observation is in concordance with other data in the literature
showing that old subjects’ dopaminergic systems undergo changes
in DA receptor density in the hippocampus (Amenta et al., 2001;
Hemby et al., 2003; Xing et al., 2010). DA D3 receptor regulates
cAMP-response element binding protein (CREB) signalling, which is
one of the cellular molecules that has been strongly implicated in
synaptic plasticity (Xing et al., 2010). Alterations in the DA D3r
signalling were reported in age-related memory and cognitive
impairment (Xing et al., 2010). Furthermore, a reduced concentra-
tion of DA in the dorsal hippocampus of aged rats (Stemmelin et al.,
2000) could render them less able to compensate for the ﬂuctu-
ating concentrations of DA resulting from pulsatile L-Dopa treat-
ment, as observed in this study.We have extended the previous observations on the constitutive
Fos expression in the rat hippocampus (Desjardins et al., 1997) by
measuring two time points between two L-Dopa administrations.
Interestingly, we have observed a spontaneously increased Fos in-
duction during the late phase of the inter-administration period in
the hippocampus. In fact, the observed cognitive impairment was
temporally mirrored by a blunted MWM-induced activation of Fos
expression in the hippocampus (Fos counts after MWM vs. Fos
counts at Basal 12 h, Fig. 4, panel F, shade areas). As we mentioned
before, there was a signiﬁcant global reduction of the ratio D5r/D3r
comparing the old treated subjects with the young ones, which
implicated a pronounced, up-regulated expression of the D3r in the
old rat’s hippocampus. D3r’s function is of particular interest
because evidence suggests its effects are primarily inhibitory
(Flores et al., 1996).
4.2. Differential effect of chronic L-Dopa treatment on mood and
cognition in young and aged intact rats
As early as 1971, Persson and Walinder reported non-
Parkinsonian human cases in which L-Dopa treatment caused
short-term alleviating but longeterm exacerbating effects on
depressive symptoms e just one month of treatment already
prompted patients with worsening of original depressive symp-
toms (Persson andWalinder, 1971). In the present study, we set out
to test the effect of a pulsatile chronic administration scheme of L-
Dopa on mood and cognition in an intact rat model, emphasizing a
comparison at two different ages.We chose a common clinical used
dose and application format. With RFST, an established and pre-
dictive animal model for the study of depression in which antide-
pressants typically reduce the duration of the immobility exhibited
(Lucki et al., 2001; Porsolt et al., 1977b), we observed that in the ﬁrst
day of the test all the experimental groups had similar perfor-
mance, discarding any possible locomotor impairment by chronic L-
Dopa treatment. In the second day of RFST, aged-treated rats
showed increased immobility compared to controls. This ﬁnding is
in accordance with a recent study that used longer and higher
doses of L-Dopa in intact young rats, and showed increased
immobility in a forced swimming test correlated with impaired DA
and serotonin metabolism in some brain areas (Borah and
Mohanakumar, 2007).
The sucrose intake test assesses another aspect of depression-
like behaviour in rats. A reduction of the sucrose liquid intake
provides an indirect measure of desensitization of the brain reward
mechanisms. Aged treated subjects had a marked reduction of su-
crose intake, indicating anhedonia which deﬁned as a lowered
ability to experience pleasure, an important component of
depression. The putative neural substrate of anhedonia is repre-
sented by the dysfunction of a dopaminergic mesolimbic reward
circuit involving the ventral striatum (nucleus accumbens), the
prefrontal cortex and the entorhinal and amygdaloid complexes
(Berke and Hyman, 2000; Kondo, 2008; Tanti and Belzung, 2010).
These structures, and particularly the dopaminergic receptors in
the nucleus accumbens, are considered to mediate the euphorising
effects of psychostimulants, antiparkinsonian drugs and gustatory
reward (Cantello et al., 1989; Norgren et al., 2006) or, as elsewhere
suggested, mediate behavioural activation and effort-related pro-
cesses (Salamone et al., 2007). Our observation suggests an alter-
ation in DA responsiveness in the above regions.
The DAr expression patterns we observed in young control rats
(Fig. 6, panels As) are in concordance with those reported in liter-
ature on the subject (Ciliax et al., 2000). The elevation of D3r in L-
Dopa treated subjects has also been reported (Joyce et al., 2004).
Conversely, we have observed signiﬁcant increases of D2r, D3r and
D5r expression the cell body layer in CA1, CA2, CA3 and DG in aged
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with a study in humans using positron emission tomography (PET)
in which a 10% of loss of D2r/D3r in the hippocampus was reported
(Kaasinen et al., 2000). One possible explanation of this discrep-
ancy is that the resolution of a PET image study is much lower than
immunohistochemistry combined with confocal microscopy as we
used in our study. The altered hippocampal D5r /D3r and D5r/D2r
ratios in the old treated group matched with lower sucrose con-
sumption and increased immobility in RFST. Given that the hip-
pocampus is involved in the feedback regulation of the HPA axis
function, structural and functional changes in hippocampus are
related to mood disorders, including depression, which could result
from an inability to appropriately respond to stress (Duman et al.,
1999). DA receptors are also implicated in the underlying mecha-
nisms in mood modulation; for example, antidepressants based on
adenosine receptor antagonists probably involve interaction with
D2 receptors (Crema et al., 2013).
4.3. Technical consideration for the usage of cumulative probability
of escape latency (CPFEL) for the Morris Water Maze test analysis
Regarding the MWM performance analysis, It is worth
mentioning that the signiﬁcant interaction between “age”, “treat-
ment” and “trial” factors made the differences observed difﬁcult to
interpret using ANOVA and the Bonferroni pos hoc test. This is a
common problem for the experiments on spatial learning such as
the MWM test: the individual differences and the not-fully pre-
dictable nature of rat behaviour increase the variation for a given
trial, and the lack of independence between the different trials. The
trial correlation is clearly observed in the experiment, and it is an
expected result for a learning-type curve, at least for the control
group. On the other hand, the variability of the response of the rat
in a speciﬁc trial could be, even less probable, a temporal behaviour
that does not necessarily reﬂect its intrinsic learning process.
Evidently, this problem can be solved increasing the n, but by using
the cumulative probability of escape latency (CPFEL), as proposed in
this study, in addition to the repeated measure ANOVA analysis,
this problem can be better solved with smaller n. Moreover, using
this probabilistic approach can reveal additional characteristics of
the rat behaviour. Firstly, the usual analysis could only report the
mean latency time of escape with its variability at a deﬁnite trial
and could not answer the question: at which time does the popu-
lation learn the task? As an example, see Fig. 3C. We could interpret
that the experimental old group learn to escape in the trial IV and
on trial V the group unlearnt it. Therefore, did the group learnt to
escape on trial IV or did they not? In our analysis it is possible to
extract this information because we answer that half of the
experimental old population was able to learn to escape on trial VI
with a time lower than 22.5 s. This information provides useful
aspects complementing those reported in the traditional analysis.
Secondly, the usual way to report the variation is to report the
standard error for each trial, because the variation of all of the trials
does not have any sense. However, with our analysis we could
report the variability of the behaviour of the population, and as can
be seen, this variability increases with the age group, as the com-
mon sense would indicate, but now in a quantitative way of testing
it. However, we have to be aware that the span of time chosen could
affect the estimators or l and k.
4.4. Conclusion remark and implications for palliative care in
Parkinson’s diseae
Receptor up- and down-regulation has long been implicated in
adaptive responses to continued pharmacological stimuli. Our re-
sults indicate that a chronic pulsatile L-Dopa treatment within thetherapeutic range could produce depression-like behaviour and
spatial learning impairment in intact rats, with aged subjects being
more vulnerable. Dopaminergic receptor dysregulation is impli-
cated as the underlying mechanism for the demonstrated
emotional and cognitive dysfunctions.
In the past, the non-motor symptoms of PD patients have
received little attention, particularly in the clinical settings
(Bunting-Perry, 2006). Patients with this disorder often develop
depression and cognitive decline culminating in dementia
(Cummings, 1992; Leverenz et al., 2009; Svenningsson et al., 2012).
The results of this study could have important implications for
elderly patients who are treated with L-Dopa for Parkinsonism and
who often develop cognitive impairment and emotional distur-
bances. Hence, this study calls attention to the need for heightened
monitoring of emotional and cognitive functions, as well as
accentuated palliative care for elderly Parkinson’s patients treated
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